Sharp downward price movements in specialty biotechnology stocks typically occur when market expectations regarding immediate post-approval sales velocity face initial commercialization realities or broader risk-off sentiment hits small-cap equities. As investors weigh the capital burn required to scale nationwide marketing and distribution against early revenue figures, temporary valuation corrections and high intraday volatility frequently manifest across trading sessions.